AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02073214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Standard treatment plus probiotic
Study NCT02073214 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard treatment plus placebo
Study NCT00417885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: 25 mg, oral, daily dosing
Study NCT00417885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: 37.5 mg, oral, continuous dosing, daily
Study NCT03659942 — intervention group
Intervention type: OTHER
Intervention: CAST questionnaire
Description: the CAST questionnaire will be used to answer the main objective of the study and to identify consumers with problematic cannabis use. This is a validated self-questionnaire in France (Legleye et al., 2011), specific to the adolescent population, which is interpreted according to the score obtained (Bastiani et al., 2013, Legleye et al. 2007, Legleye et al., 2011). It includes 6 items with answer modes coded from 0 to 4. The total score obtained by summing these 6 items can therefore vary from 0 to 24. We define users without risk for a score of less than 3, users with low risk for a score greater than or equal to 3 and less than 7, and finally those with a risk of problematic use for a score greater than or equal to 7
Study NCT02859233 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lack of hyperhydration
Study NCT04424238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: m-health management
Description: Patients in intervention group received additional WeChat group management when conducted standard clinic prenatal care.
Study NCT04037319 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 24 Hour Holter Monitor
Description: 24 hour holter monitor to be performed pre-operatively, and at day 30 and 90 post-operatively.
Study NCT01223014 — intervention group
Intervention type: DRUG
Intervention: AZD2423
Description: AZD2423
Study NCT03823794 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Observational analysis of usual care only
Study NCT01958775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-2
Description: single subcutaneous dose of 1500mcg
Study NCT01958775 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04222569 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T-piece
Description: Spontaneous breath trial with a T-piece
Study NCT04249440 — intervention group
Intervention type: PROCEDURE
Intervention: Preoperative systemic treatment
Description: neoadjuvant chemotherapy combined with trastuzumab as preoperative systemic treatment
Study NCT01771445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IL-1Ra
Description: 100mg, s.c, once only
Study NCT01771445 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100mg, s.c., once only
Study NCT02553408 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: FreeStyle Precision Neo-Meter
Description: Participants will receive a free glucose meter (Neo) and test strips from their care providers with education and instructions on how to use the meter to monitor their glucose level. Three months after the start of using the meter, participants will be interviewed on their experiences, likes and dislikes about the meter.
Study NCT01675362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antioxidant group
Description: They will be receive vitamins A, C, E and selenium (Selenium ACE) Dosage: Two tablets before ESWL Then 2 tablets every 8 hours after ESWL for one week
Study NCT01675362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Channel Blockers
Description: They will receive Verapamil (Isoptin 80 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every 12 hours after ESWL for one week
Study NCT01675362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angiotensin receptor blocker group
Description: They will receive Losartan (Cozaar 50 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every day after ESWL for one week
Study NCT01675362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: They will receive placebo
Study NCT03437707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
Study NCT03437707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine Sulfate
Description: Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
Study NCT03437707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous paracetamol
Description: 1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
Study NCT03437707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous ibuprofen
Description: 800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
Study NCT02152774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rho-Kinase Inhibitor
Study NCT01946126 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention in this study.
Study NCT03743688 — intervention group
Intervention type: BIOLOGICAL
Intervention: Influenza Vaccine Recipients
Description: 0.5 mL intramuscular injection
Study NCT03136861 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AIN457
Description: anti IL-17a monoclonal antibody
Study NCT03136861 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: AIN457
Description: anti IL-17a monoclonal antibody
Study NCT03136861 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457
Description: anti IL-17a monoclonal antibody
Study NCT03778385 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Submaximal exercise is performed in randomized order with the participant seated and the arm supported in an adjustable hand-arm orthosis.
Study NCT06089902 — intervention group
Intervention type: PROCEDURE
Intervention: unroofing or other surgery if needed
Description: unroofing of coronary artery
Study NCT03136861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AIN457 Placebo
Description: Placebo matching AIN457
Study NCT01828411 — intervention group
Intervention type: DEVICE
Intervention: Transpharyngeal ultrasonography
Description: Transpharyngeal Dopplerultrasonography (Device: iE33 xMatrix Philips). Assessment of cerebral blood flow by detection of blood flow velocities in the extracranial carotid arteries.
Study NCT01668017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Description: Subjects with solid tumor will be administered with Pimasertib 30 mg twice a day (BID) in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
Study NCT03136861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AIN457 Placebo
Description: Placebo matching AIN457
Study NCT00982527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Saline continuous infusion during cardiopulmonary by pass at 1 ml/h
Study NCT00982527 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline continuous infusion during cardiopulmonary by pass at 1 ml/h
Study NCT00982527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenoldopam
Description: Fenoldopam continuous infusion at 1 mcg/kg/min during cardiopulmonary bypass. Infusion preparation is mad in order to match the rate 1 ml/h of placebo infusion.
Study NCT01668017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Description: Subjects with solid tumor will be administered with Pimasertib 45 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
Study NCT01668017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Description: Subjects with solid tumor will be administered with Pimasertib 60 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
Study NCT01828411 — intervention group
Intervention type: DEVICE
Intervention: Duplex sonography
Description: Assessment of cerebral blood flow by detection of blood flow velocities in the extracranial carotid and middle cerebral arteries during coronary artery bypass grafting.
Study NCT01205477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPERIMENTAL
Description: Infiltration of 40 mg of methylprednisolone acetate plus 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days
Study NCT01205477 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Infiltration of 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days
Study NCT01571856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinc Sulfate
Description: zinc sulfate solution, contains 20 mg. per 5 mL. dosage 2.5 mL. per day.
Study NCT01571856 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: cornstarch powder diluted in distilled water, dosage 2.5 ml per day
Study NCT01729208 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual Focus Soft Contact Lens
Study NCT01729208 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Single Vision Soft Contact Lens
Study NCT01613430 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Printed Educational Materials (PEM)
Description: Participants and their coaches will be provided with educational brochures about cancer screening for colorectal, breast and cervical cancers at the completion of the baseline survey.
Study NCT00982527 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fenoldopam
Description: Fenoldopam continuous infusion at 1 mcg/kg/min during cardiopulmonary bypass. Infusion preparation is mad in order to match the rate 1 ml/h of placebo infusion.
Study NCT00584909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel and carboplatin combination
Description: Paclitaxel will be administered at an appropriate dose (175 mg/m2) as a 3-hour continuous IV infusion every 21 days. Carboplatin will be administered at an appropriate dose utilizing the Calvert formula for determining the area under the curve (AUC) based on the patient's glomerular filtration rate (GFR).
Study NCT00689416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: 40 mg, tablet, once daily for 3 months.
Study NCT00689416 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 40 mg, tablet, once daily for 3 months
Study NCT04353856 — intervention group
Intervention type: OTHER
Intervention: quality of life assessment
Description: quality of life assessment using the EQ5D questionnaire once a month
Study NCT01668017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Description: Subjects with HCC will be administered with Pimasertib 30 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
Study NCT01668017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Description: Subjects with HCC will be administered with Pimasertib 45 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
Study NCT02763657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI scanning
Description: All participants are scanned while evaluating linear-order and set-inclusion reasoning problems
Study NCT02613767 — intervention group
Intervention type: OTHER
Intervention: Protein meal
Description: Ingestion of protein
Study NCT02613767 — intervention group
Intervention type: OTHER
Intervention: L-[ring 13C6]Phenylalanine infusion
Description: experimental method for determining protein synthesis rates
Study NCT03572790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride
Description: 1mg prucalopride capsule, once daily for seven days
Study NCT03572790 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose placebo capsule, once daily for seven days
Study NCT02025439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Study NCT04148573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NFX88 - 1
Description: 3 times a day
Study NCT04148573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NFX88 - 2
Description: 3 times a day
Study NCT04148573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NFX88 - 3
Description: 3 times a day
Study NCT04148573 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO - 4
Description: 3 times a day
Study NCT02025439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine
Study NCT02297672 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stranded palladium seed interstitial implant
Description: Interstitial implantation of stranded palladium 103 seeds in seroma with a margin
Study NCT02297672 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3 dimensional breast ultrasound
Description: guidance of placement of interstitial needles in breast
Study NCT02297672 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computerized tomography (CT)
Description: Breast CT for planning and assessing interstitial implantation of radioactive seeds
Study NCT03053466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-501
Description: Subjects will be assigned to a dose level in the order of study entry. Treatment includes a minimum of four 28-day cycles at three planned dose levels (1, 3, and 10 mg/kg). In the Dose Escalation Segment, each treatment cycle is comprised of 2 doses of study drug administered on Days 1 and 15 of a 28-day cycle. In the Cohort Extension, the treatment cycle will consist of 2 doses of study drug administered on Days 1 and 15 of a 28-day cycle.~In Dose and Disease Expansion, the treatment cycle will consist of 2 doses of study drug (non-weight based dosing of 400 mg) administered on Days 1 and 15 of a 28-day cycle.
Study NCT03854630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Engerix-B
Description: The vaccine contains HBsAg which was produced by genetic engineering yeast. It stimulates the active immunity generated by human immune system toward the HBsAg.
Study NCT03854630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B
Description: The vaccine contains HBsAg which was produced by genetic engineering yeast. It stimulates the active immunity generated by human immune system toward the HBsAg.
Study NCT01816555 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Subjects will be assigned to a dosage level between 600IU daily and 10,000IU daily depending on their age, weight and current vitamin D level
Study NCT02655575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BI + VR + CBT
Description: Brief intervention (information and advice) + group-based vestibular rehabilitation combined with cognitive behavioral therapy
Study NCT02655575 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BI + VR + CBT
Description: Brief intervention (information and advice) + group-based vestibular rehabilitation combined with cognitive behavioral therapy
Study NCT02655575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BI + phone calls
Description: Brief intervention (information and advice). Patients are followed-up by phone calls
Study NCT01354288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational tool
Description: Specific educational tool in order to assess its impact on glycemic control, quality of life, knowledge about the disease and its daily management
Study NCT03558438 — intervention group
Intervention type: OTHER
Intervention: No interventions
Description: No interventions
Study NCT02655575 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BI + phone calls
Description: Brief intervention (information and advice). Patients are followed-up by phone calls
Study NCT01026740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftobiprole
Description: single intravenous (i.v.) infusion, 500 mg ceftobiprole administered over 2 hours.
Study NCT01441700 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prone and Supine emergence from anaesthesia
Description: Aims: The aim of this study was to compare haemodynamic changes and to evaluate the incidence of coughing, laryngospasm, loss of monitoring in patients undergoing lumbar disc surgery extubated in prone position and supine position. Settings and design: This open-level prospective randomized study was carried out in 50 patients who were admitted for elective lumbar surgery. Methods: The patients were randomly allocated to one of the two groups of 25 each at conclusion of surgery. First group was extubated in prone position and second in supine position at conclusion of surgery. Supine group patients were rolled back and prone group patients were left undisturbed. Extubation was done after complete reversal of neuromuscular block. Heart rates, Mean Arterial Pressure were noted at various points of time. Coughing, laryngospasm, vomiting, monitor disconnection if any were also noted. Statistical methods: Data was analyzed using
Study NCT04237246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 24 hour long acting advegraf
Study NCT00868036 — intervention group
Intervention type: PROCEDURE
Intervention: Patch Testing
Description: Patch testing will be performed with a modified North American Contact Dermatitis Group (NACDG) standard series, cosmetics/preservative, fragrance, and textile series in all patients. Based on patient history, other appropriate allergen series will be added. After two days, patches will be removed and the areas will be inspected for type IV hypersensitivity reactions including papules, edema or vesicles.~Results will be graded and interpreted at a delayed read, 3-4 days after allergens are placed with patch testing.
Study NCT03693989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difluprednate 0.05%
Description: Dosage: 1 drop 4 times a day (every 4 hours) during the period of vigil in the operated eye, for 14 days. Dose reduction for 14 days at the discretion of the principal investigator.
Study NCT03693989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednefrin
Description: 1 drop 4 times a day (every 4 hours) during the period of vigil in the operated eye, for 14 days. Dose reduction for 14 days at the discretion of the principal investigator.~- Route of administration: topical ophthalmic
Study NCT02782260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Study NCT04755452 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low intra-abdominal pressure
Description: 7 mm Hg pneumoperitoneum during robot-assisted laparoscopic surgery
Study NCT04755452 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High (standard) intra-abdominal pressure
Description: 12 mm Hg pneumoperitoneum during robot-assisted laparoscopic surgery
Study NCT02782260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00457314 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Regular exercise training
Study NCT01017159 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Subcutaneous immunoglobulin
Description: The subcutaneous immunoglobulin is infused in the subcutaneous tissue on the abdomen twice or thrice a week, with a maximal speed of 2 mL/h. Every time 20 mL is infused, the needle is removed to a new place.
Study NCT01017159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous immunoglobulin
Description: The subcutaneous immunoglobulin is infused in the subcutaneous tissue on the abdomen twice or thrice a week, with a maximal speed of 2 mL/h. Every time 20 mL is infused, the needle is removed to a new place.
Study NCT00801606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc
Description: Zinc 20 mg/day
Study NCT00801606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronutrient without zinc
Description: Multimineral 2 RDA